Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected to Post FY2026 Earnings of $1.03 Per Share

Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Get Rating) – Oppenheimer issued their FY2026 EPS estimates for shares of Milestone Pharmaceuticals in a research note issued to investors on Monday, April 25th. Oppenheimer analyst L. Gershell forecasts that the company will earn $1.03 per share for the year.

Several other equities analysts have also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating on shares of Milestone Pharmaceuticals in a research note on Tuesday, March 29th. Zacks Investment Research cut shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 30th. Finally, Piper Sandler upgraded shares of Milestone Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $8.00 to $10.00 in a research note on Thursday, April 21st.

MIST stock opened at $7.01 on Tuesday. The firm’s fifty day simple moving average is $6.05 and its 200-day simple moving average is $6.27. The company has a market capitalization of $209.72 million, a P/E ratio of -6.87 and a beta of 3.50. Milestone Pharmaceuticals has a 12 month low of $3.98 and a 12 month high of $8.24.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Rating) last released its quarterly earnings data on Thursday, March 24th. The company reported ($0.40) EPS for the quarter.

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. acquired a new position in Milestone Pharmaceuticals during the fourth quarter worth $46,000. Acadian Asset Management LLC raised its position in Milestone Pharmaceuticals by 63.0% during the fourth quarter. Acadian Asset Management LLC now owns 12,381 shares of the company’s stock worth $79,000 after acquiring an additional 4,785 shares during the period. National Bank of Canada FI acquired a new position in Milestone Pharmaceuticals during the fourth quarter worth $96,000. Royal Bank of Canada raised its position in Milestone Pharmaceuticals by 13,063.3% during the third quarter. Royal Bank of Canada now owns 26,195 shares of the company’s stock worth $149,000 after acquiring an additional 25,996 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Milestone Pharmaceuticals by 15.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 52,578 shares of the company’s stock worth $345,000 after acquiring an additional 7,061 shares during the period. Institutional investors own 66.89% of the company’s stock.

About Milestone Pharmaceuticals (Get Rating)

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

Featured Articles